• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h ventures makes an investment into digital therapeutic Cortirio…
o2h ventures makes an investment into digital therapeutic Cortirio…
Oct 15 2020

Cambridge, UK, October 2020: The o2h human health EIS Fund, is pleased to lead an investment into digital therapeutic Cortirio Limited alongside University of Surrey and KQ Labs. Traumatic brain injury is the leading cause of death and disability among the under 45s and a growing problem for our aging population as falls become more prevalent. Cortirio’s portable scanners can be used at the point of care to enable the early treatment of traumatic brain injuries. By saving time, this technology will save brain function and avert disability and death

Sunil Shah, CEO at o2h Ventures said: “We are very excited to invest into Cortirio’s portable brain scanner.  When fully developed this could be supportive to the NHS and to other health systems around the world”

Patrick Beldon, CEO and Co-Founder at Cortirio said: “We are very happy to bring on o2h ventures as an investor as they are a value adding investor with the business and technology experience and global networks to help us commercialise our product.”

Caroline Fleming, Interim Director of Innovation Strategy at the University of Surrey said: “The University of Surrey is excited to have developed an investment strategy to support pioneering businesses in the University’s Innovation Ecosystem. We are delighted with the growth we have seen Cortirio achieve since joining SETsquared Surrey and are pleased to contribute to the funding required to commercialise the Cortirio technology that can save lives and reduce NHS costs.”

Editor’s Note:

About o2h ventures:

The o2h human health EIS Fund is the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit www.o2hventures.com

Media Contact:

Ajit Singh

Marketing Manager

ajit@o2h.com

About Cortirio:

Cortirio’s mission is to improve and save lives using medical imaging. Cortirio’s first application is for traumatic brain injuries, which kill 1 million people and leave 7.5 million people disabled each year. Fast treatment is vital for head injuries but 40% of all head injuries are not recognised within 12 hours. Cortirio is developing portable brain imaging which can be used at the scene of an injury to reduce time-to-treatment and save lives.

For more information, please visit http://cortirio.com

Contact:

Patrick Beldon

CEO

patrick@cortirio.com

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science 28 Feb 2023
  • o2h-ventures Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 Jan 2023
  • o2h-ventures o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 Jan 2023
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)